Meeting
2023 ASCO Annual Meeting
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
Presenter
Yuval Shaked, PhD, BSc
Technion
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2557)
DOI
10.1200/JCO.2023.41.16_suppl.2557
Abstract #
2557
Poster Bd #
399
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy.
Speaker: Max Julve, MBBS
Videos & Slides
2021 ASCO Annual Meeting
Improving patient and caregiver understanding of risks and benefits of immunotherapy for melanoma or lung cancer.
Speaker: Laura A Petrillo, MD
Videos & Slides
2021 ASCO Annual Meeting
Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced lung cancer or melanoma.
Speaker: Laura A Petrillo, MD
Videos & Slides
2011 ASCO Annual Meeting
Can We Identify Predictive Biomarkers for Response to Immunotherapy in Melanoma?
Speaker: Thomas Gajewski, MD, PhD